Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the... see more

NDAQ:ACST - Post Discussion

Acasti Pharma Inc > Do the Math
View:
Post by hydrocarbss on Jun 20, 2020 6:28am

Do the Math

We aren't given the exact breakdown for the Trilogy 1 trial.

So will use approximations.

Trilogy 1 enrolled 242 particpants

121 in the placebo          121 in the Capre

The placebo arm had 36% of participants in the 5 trial sites with issues.

36% of 121 is 43.  The other 78 had 'within range' placebo effect, a guess.

The placebo arm showed an overall reduction of 27.5% of triglycerides.

That is the average for all 121.  Those 43 must have had huge reduction numbers.

Trial was for people with triglyceride blood levels from 500 mg/dL to 1500 mg/d

Those 43 with the huge reduction 
 
Add  78 with normal placebo response

And the entire group average 27.5% reduction....

Two (of 78) with placebo reduction of 10% would mean one (of 43) in the suspect sites would have to have a 62.5% drop on TG's in order for those three to average a 27.5% reduction...

Crazy mixup...
Comment by Danny1082Man on Jun 20, 2020 7:35am
I will have to look it up but I thought the number of patients assigned was 2.5:1 for CaPre verses Placebo
Comment by lscfa on Jun 20, 2020 9:34am
Study Description   Go to   Brief Summary: The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared to placebo, in lowering fasting triglyceride (TG) levels in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L) after 12 weeks of treatment. Approximately 615 subjects will be ...more  
Comment by lscfa on Jun 20, 2020 9:42am
    25 Patients   Pacebo       5   5   5   5  ...more  
Comment by hydrocarbss on Jun 20, 2020 9:57am
Thanks, did this after staying up all night...
Comment by lscfa on Jun 20, 2020 9:57am
Does each site maintain the 2.5-to-1 ratio or is that a study wide goal? If study is truly double blinded  then ratio may vary from site to site. Did the 5 bad sites have a higher no. of placebo patients than overall goal?  
Comment by Danny1082Man on Jun 20, 2020 1:36pm
2.5:1 is full study. Some sites only have a couple of patients
Comment by Danny1082Man on Jun 20, 2020 1:38pm
Exact reason why the call on the 29th is so important. How many placebo patients were at the site? Could, we hope, a disproportionate amount were from there, or that will be a huge concern
Comment by Danny1082Man on Jun 20, 2020 7:37am
And your assumption I believe is wrong. They take the median, not the average of placebo reduction
Comment by Danny1082Man on Jun 20, 2020 1:45pm
Trilogy 1 would have 175 on CaPre and 70 on placebo. So you would need 36 high placebo out of 248 subjects to torpedo the study. How many of the 35 placebo were at those 5 sites? That's the golden ticket question
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities